• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: BeiGene     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingcompanyschema:Organizationdul:Agentdul:SocialPersonagentwikidata:Q24229398OrganizationBusiness enterpriseorganisation New Facet based on Instances of this Class

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019.